Skip to main content
Top

22-01-2024 | AL Amyloidosis | Nephrology Image

Silver-positive kidney AL amyloidosis

Authors: Francesco Fontana, Gaetano Alfano, Laura Verga, Riccardo Magistroni, Gabriele Donati

Published in: Journal of Nephrology

Login to get access

Excerpt

Glomerular amyloid deposits typically involve the mesangium and are described as acellular, amorphous and negative with Jones methenamine silver stain [1]. A 71-year-old While male patient with a history of kappa light chain-only smoldering multiple myeloma underwent percutaneous kidney biopsy for nephrotic range proteinuria. Light microscopy showed diffuse and global amorphous mesangial deposits, which appeared intensely silver-positive, staining in black (Fig. 1A); segmental spicules departing from capillary loops were also visible (Fig. 1, panel A, arrow). Deposits stained positive with Congo red and showed typical apple-green birefringence under polarized light (Fig. 2A). Immunofluorescence identified kappa light chain restriction (Fig. 3). Electron microscopy confirmed the presence of mesangial randomly arranged fibrils with a diameter of 7–12 nm, positive for kappa light chain with immunogold labeling (Fig. 2B). A diagnosis of kidney limited monoclonal light chain (AL) amyloidosis was made. Silver-negativity of amorphous mesangial deposits is one of the classical morphological features of kidney AL amyloidosis [1]. Silver-positive kidney amyloid deposits have been previously described only in heavy chain or light-and-heavy chain amyloidosis, and are a relatively rare occurrence (6% of cases) [2].
Metadata
Title
Silver-positive kidney AL amyloidosis
Authors
Francesco Fontana
Gaetano Alfano
Laura Verga
Riccardo Magistroni
Gabriele Donati
Publication date
22-01-2024
Publisher
Springer International Publishing
Published in
Journal of Nephrology
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01827-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.